Shots:

• Coave to receive $11.7M up front & equity investment- ~ $76.5M as clinical development- regulatory & commercial milestones along with royalties on net sales of the product. Both companies will co-develop Coave's CTx-PDE6b & share the development costs
• Théa obtains an exclusive license to commercialize the therapy in the EU- Ukraine- Turkey- Russia- and North Africa. Coave retains the rights to commercialize CTx-PDE6b in the US
• CTx-PDE6b is a novel AAV-based gene therapy that is designed to deliver a non-mutated copy of the PDE6b gene into the subretinal space. The therapy is currently being evaluated in the P-I/II trial to determine its safety & efficacy

  | Ref: PR Newswire | Image: Coave Therapeutics